Drugs / S-warfarin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02567682 | Sep 2015 → May 2016 | sickle cell disease | Global Blood Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01517399 | Dec 2011 → Aug 2013 | cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01462318 | Nov 2011 → Jan 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S warfarin | “GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam” NCT02567682 ↗ |
| Route | Oral | “S-warfarin 10 mg” NCT01462318 ↗ |